Real-World Effectiveness and Safety of Pre-mix 70/30 Insulin Initiation in Poorly Controlled Type 2 Diabetes: a Multicentre Pakistani Cohort
INTRODUCTION: In lower- and middle-income countries, insulin choice at initiation is driven as much by cost as by clinical need. Low-cost human pre-mix 70/30 insulin predominates in Pakistan, yet prospective real-world evidence on its outcomes and true cost is scarce. METHODS: In this investigator-initiated, single-arm, prospective observational study at 12 sites in Pakistan, insulin-naïve adults with type 2 diabetes and HbA1c 9% or higher despite two or more oral drugs were started on human pre-mix 70/30 insulin at physician discretion and followed for 6 months, with assessments at baseline, day 90 and day 180. The primary outcomes were change in HbA1c and incidence of hypoglycaemia (classified by American Diabetes Association levels). A descriptive cost-consequence analysis (patient out-of-pocket perspective) was a pre-specified secondary exploratory objective. RESULTS: A total of 384 of 430 screened patients were enrolled, with a mean baseline HbA1c of 11.2 ± 1.5%. HbA1c fell to 9.3 ± 1.5% at day 90 and to 8.8 ± 1.5% at day 180, a mean reduction of 2.3 ± 1.8% (p < 0.001), with no significant change in body weight. By day 180, 242 of 310 patients (78.1%) had achieved at least a 1% reduction in HbA1c, and 28 patients (9.0%) reached below 7%. Confirmed hypoglycaemia below 70 mg/dL occurred in eight patients (2.1%), and no severe or treatment-limiting events were recorded. Mean 6-month direct medical cost was 36,269 Pakistani Rupee (PKR) per patient. Insulin acquisition accounted for just PKR 7200 of this (19.8%), while consultations, injection consumables, diagnostics and self-monitoring made up the remainder. CONCLUSIONS: In routine practice, human pre-mix 70/30 insulin produced clinically meaningful and sustained HbA1c reductions with a favourable safety profile, supporting its effectiveness for insulin initiation in poorly controlled type 2 diabetes. Affordability, however, was governed by the total cost of care rather than insulin price alone.
Authors
- Riasat Ali Khan
- Gohar Ali Khan
- Syed Abbas Raza (ORCID: https://orcid.org/0000-0003-4270-7939)
- Mazhar Faiz Alam
- Amena Moazzam Baig
- Uneeba Syed
- Ibrar Ahmad (ORCID: https://orcid.org/0000-0002-9808-8236)
- Azizul Hasan Aamir (ORCID: https://orcid.org/0000-0002-5477-0559)
- Saeed Ahmed Mahar (ORCID: https://orcid.org/0009-0007-8431-4566)
- Faisal Masood Qureshi
- Hafiz Farhan Rashid
- Mohammad Imtiaz Hassan
Institutions
- Punjab Institute of Cardiology (PK)
- Allama Iqbal Medical College (PK)
- Lady Reading Hospital (PK)
- Indus Hospital (PK)
- Bahawal Victoria Hospital (PK)
- Northwest General Hospital and Research Center (PK)
- Shaukat Khanum Memorial Cancer Hospital and Research Center (PK)
- National Institute of Cardiovascular Diseases (PK)
- National Hospital and Medical Center (PK)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s13300-026-01939-4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00